{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:32:08Z","timestamp":1793039528790,"version":"4.5.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,1,23]],"date-time":"2013-01-23T00:00:00Z","timestamp":1358899200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagn Pathol"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1186\/1746-1596-8-11","type":"journal-article","created":{"date-parts":[[2013,1,23]],"date-time":"2013-01-23T11:51:22Z","timestamp":1358941882000},"source":"Crossref","is-referenced-by-count":74,"title":["Significance of HE4 estimation in comparison with CA125 in diagnosis of ovarian cancer and assessment of treatment response"],"prefix":"10.1186","volume":"8","author":[{"given":"Elham O","family":"Hamed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hydi","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osama B","family":"Sedeek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abeer M","family":"Mohammed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali A","family":"Abd-Alla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hazem M Abdel","family":"Ghaffar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,1,23]]},"reference":[{"issue":"1","key":"730_CR1","first-page":"15","volume":"4","author":"JA Rauh-Hain","year":"2011","unstructured":"Rauh-Hain JA, Krivak TC, del Carmen MG, Olawaiye AB: Ovarian cancer screening and early detection in the general population. Rev Obstet Gynecol. 2011, 4 (1): 15-21.","journal-title":"Rev Obstet Gynecol"},{"key":"730_CR2","first-page":"113","volume-title":"pathology and genetics of tumours of the breast and female genital organs","author":"KR Lee","year":"2003","unstructured":"Lee KR, Tavassoli FA, Prat J, Dietel M, Gersell DJ, Karseladze AI, Hauptmann S, Rutgers J: WHO histological classification of tumours of the ovary (chapter 2). pathology and genetics of tumours of the breast and female genital organs. Edited by: Tavassoli FA, Devilee P. 2003, Lyon: IARC Pres, 113-161."},{"issue":"1","key":"730_CR3","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ygyno.2008.09.043","volume":"112","author":"B Nolen","year":"2009","unstructured":"Nolen B, Marrangoni A, Velikokhatnaya L, Prosser D, Winans M, Gorelik E, Anna LA: A serum based analysis of ovarian epithelial tumorigenesis. Gynecol Oncol. 2009, 112 (1): 47-54.","journal-title":"Gynecol Oncol"},{"issue":"7","key":"730_CR4","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/j.humpath.2011.03.003","volume":"42","author":"RJ Kurman","year":"2011","unstructured":"Kurman RJ, Shih I-M: Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer-shifting the paradigm. Hum Pathol. 2011, 42 (7): 918-931.","journal-title":"Hum Pathol"},{"key":"730_CR5","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/1746-1596-7-124","volume":"7","author":"O Hatice","year":"2012","unstructured":"Hatice O, GoncaImir Y, Sema A, Meral C, Ersin T, Ali C: Immunohistochemistry with apoptotic-antiapoptotic proteins (p53, p21, bax, bcl-2), c-kit, telomerase, and metallothionein as a diagnostic aid in benign, borderline, and malignant serous and mucinous ovarian tumors. Diagn Pathol. 2012, 7: 124-","journal-title":"Diagn Pathol"},{"key":"730_CR6","first-page":"337","volume":"92","author":"R Fauvet","year":"2005","unstructured":"Fauvet R, Dufornet C, Poncelet C, Uzan C, Hugol D, Darai E: Expression of Pro apoptotic (p53, p21, bax, bak and fas) and anti-apoptotic (bcl-2 and bcl-x) proteins in serous versus mucinous borderline ovarian tumours. J SurgOncol. 2005, 92: 337-343.","journal-title":"J SurgOncol"},{"key":"730_CR7","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1111\/j.1048-891X.2004.14606.x","volume":"14","author":"JS Nielsen","year":"2004","unstructured":"Nielsen JS, Jakobsen E, Holund B, Bertelsen K, Jakobsen A: Prognostic significance of p53, Her-2, and EGFR overexpression in borderline and epithelial ovarian cancer. Int J Gynecol Cancer. 2004, 14: 1086-1096.","journal-title":"Int J Gynecol Cancer"},{"key":"730_CR8","doi-asserted-by":"publisher","first-page":"3814","DOI":"10.1200\/JCO.2003.11.052","volume":"21","author":"L Havrilevsky","year":"2003","unstructured":"Havrilevsky L, Darcy K, Hamdan R, Priore RL, Leon J, Bell J, Berchuck A: Prognostic significance of p53 mutation and p53 overerpression in advanced epithelial ovarian cancer: a gynecologic oncology group study. J Clin Oncol. 2003, 21: 3814-3825.","journal-title":"J Clin Oncol"},{"key":"730_CR9","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/1746-1596-5-78","volume":"5","author":"A Viren","year":"2010","unstructured":"Viren A, Raheela K, Averil W, Robert S, Schalkwyk GV, Anish B, Sowter HM: The Eag potassium channel as a new prognostic marker in ovarian cancer. Diagn Pathol. 2010, 5: 78-","journal-title":"Diagn Pathol"},{"key":"730_CR10","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.bpobgyn.2003.10.002","volume":"18","author":"L Valentin","year":"2004","unstructured":"Valentin L: Use of morphology to characterize and manage common adnexal masses. Best Pract Res Clin Obstet Gynaecol. 2004, 18: 71-89.","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"730_CR11","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.ygyno.2005.06.040","volume":"99","author":"DG Rosen","year":"2005","unstructured":"Rosen DG, Wang L, Atkinson JN: Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol. 2005, 99: 267-277.","journal-title":"Gynecol Oncol"},{"key":"730_CR12","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1006\/gyno.1994.1179","volume":"54","author":"T Maggino","year":"1994","unstructured":"Maggino T, Gadducci A, D\u2019Addario V: Prospective multicenter study on CA125 in postmenopausal pelvic masses. Gynecol Oncol. 1994, 54: 117-123.","journal-title":"Gynecol Oncol"},{"key":"730_CR13","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1111\/j.1525-1438.2007.01035.x","volume":"18","author":"H Kobayashi","year":"2008","unstructured":"Kobayashi H, Yamada Y, Sado T: A randomized study of screening for ovarian cancer: a multicenter study in Japan. Int J Gynecol Cancer. 2008, 18: 414-420.","journal-title":"Int J Gynecol Cancer"},{"key":"730_CR14","first-page":"2223","volume":"63","author":"GM Yousef","year":"2003","unstructured":"Yousef GM, Polymeris ME, Yacoub GM: Parallel overexpression of seven kallikrein genes in ovarian cancer. Cancer Res. 2003, 63: 2223-2227.","journal-title":"Cancer Res"},{"key":"730_CR15","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/modpathol.3800612","volume":"19","author":"MT Galgano","year":"2006","unstructured":"Galgano MT, Hampton GM, Frierson HF: Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol. 2006, 19: 847-853.","journal-title":"Mod Pathol"},{"key":"730_CR16","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1158\/0008-5472.CAN-04-3924","volume":"65","author":"R Drapkin","year":"2005","unstructured":"Drapkin R, von Horsten HH, Lin Y: Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res. 2005, 65: 2162-2169.","journal-title":"Cancer Res"},{"key":"730_CR17","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1016\/j.cca.2011.04.028","volume":"412","author":"G Ruggeri","year":"2011","unstructured":"Ruggeri G, Bandiera E, Zanotti L, Belloli S, Ravaggi A, Romani C: HE4 and epithelial ovarian cancer: comparison and clinical evaluation of two immunoassays and a combination algorithm. Clin Chim Acta. 2011, 412: 1447-1453.","journal-title":"Clin Chim Acta"},{"key":"730_CR18","first-page":"475983","volume":"2011","author":"BJD Rien","year":"2011","unstructured":"Rien BJD, Gupta S, Dada R, Safi J, Michener C, Agarwal A: Potential markers for detection and monitoring of ovarian cancer. J Oncology. 2011, 2011: 475983-","journal-title":"J Oncology"},{"issue":"Suppl 4","key":"730_CR19","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/annonc\/mdp117","volume":"20","author":"S Aebi","year":"2009","unstructured":"Aebi S, Castiglione M: Newly and relapsed epithelial ovarian carcinoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009, 20 (Suppl 4): 21-23.","journal-title":"Ann Oncol"},{"key":"730_CR20","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.1373\/clinchem.2008.105601","volume":"54","author":"CM Sturgeon","year":"2008","unstructured":"Sturgeon CM, Duffy MJ, Stenman U-H: National academy of clinical biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem. 2008, 54: e11-e79.","journal-title":"Clin Chem"},{"key":"730_CR21","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1200\/JCO.2003.01.068","volume":"21","author":"RC Bast Jr","year":"2003","unstructured":"Bast RC: Status of tumor markers in ovarian cancer screening. J Clin Oncol. 2003, 21: 200-205.","journal-title":"J Clin Oncol"},{"key":"730_CR22","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.ajog.2010.03.043","volume":"203","author":"RG Moore","year":"2010","unstructured":"Moore RG, Jaube-Raughley M, Brown AK: Comparison of a novel multiple marker assay vs. The risk of malignancy index for the prediction of epithelial ovarian cancer in patients with a pelvic mass. Am J Obstet Gynecol. 2010, 203: e1-e6.","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"730_CR23","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1515\/CCLM.2011.085","volume":"49","author":"YM Kim","year":"2011","unstructured":"Kim YM, Whang DH, Park J, Kim SH, Lee SW, Park HA, Ha M, Choi KH: Evaluation of the accuracy of serum human epididymis protein 4 in combination with CA125 for detecting ovarian cancer: a prospective case\u2013control study in a Korean population. Clin Chem Lab Med. 2011, 49 (3): 527-534.","journal-title":"Clin Chem Lab Med"},{"key":"730_CR24","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1038\/sj.bjc.6605011","volume":"100","author":"K Huhtinen","year":"2009","unstructured":"Huhtinen K, Suvitie P, Hiissa J, Junnila J, Huvila J, Kujari H: Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. Br J Cancer. 2009, 100: 1315-1319.","journal-title":"Br J Cancer"},{"key":"730_CR25","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1016\/j.fertnstert.2009.10.038","volume":"94","author":"L Bordin","year":"2010","unstructured":"Bordin L, Fiore C, Don\u00e0 G, Andrisani A, Ambrosini G, Faggian D: Evaluation of erythrocyte band 3 phosphotyrosine level, glutathione content, CA-125, and human epididymal secretory protein E4 as combined parameters in endometriosis. Fertil Steril. 2010, 94: 1616-1621.","journal-title":"Fertil Steril"},{"key":"730_CR26","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1586\/erm.09.39","volume":"9","author":"J Li","year":"2009","unstructured":"Li J, Dowdy S, Tipton T: HE4 as a biomarker for ovarian and endometrial cancer management. Expert Rev Mol Diagn. 2009, 9: 555-566.","journal-title":"Expert Rev Mol Diagn"},{"key":"730_CR27","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1002\/jcla.20340","volume":"23","author":"M Montagnana","year":"2009","unstructured":"Montagnana M, Lippi G, Ruzzenente O: The utility of serum human epididymis protein 4 (HE4) in patients with a pelvic mass. Clin Lab Anal. 2009, 23: 331-335.","journal-title":"Clin Lab Anal"},{"issue":"5","key":"730_CR28","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1038\/sj.bjc.6606092","volume":"104","author":"T Gorp","year":"2011","unstructured":"Gorp T, Cadron I, Despierre E, Daemen A, Leunen K, Amant F: HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the risk of ovarian malignancy algorithm. Br J Cancer. 2011, 104 (5): 863-870.","journal-title":"Br J Cancer"},{"issue":"3","key":"730_CR29","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1515\/CCLM.2011.075","volume":"49","author":"M Montagnana","year":"2011","unstructured":"Montagnana M, Danese E, Ruzzenente O, Bresciani V, Nuzzo T, Gelati M: The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful?. Clin Chem Lab Med. 2011, 49 (3): 521-525.","journal-title":"Clin Chem Lab Med"},{"issue":"6","key":"730_CR30","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1007\/s13277-011-0204-3","volume":"32","author":"M Rafael","year":"2011","unstructured":"Rafael M, Escudero JM, Aug\u00e9 JM, Xavier F, Laura F, Aureli T, Jose L, Jaume P: HE4 a novel tumour marker for ovarian cancer: comparison with CA125 and ROMA algorithm in patients with gynecological diseases. Tumour Biol. 2011, 32 (6): 1087-1095.","journal-title":"Tumour Biol"},{"key":"730_CR31","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1016\/j.clinbiochem.2011.04.011","volume":"44","author":"Y Park","year":"2011","unstructured":"Park Y, Lee JH, Hong DJ, Lee EY, Kim HS: Diagnostic performances of HE4 and CA125 for the detection of ovarian cancer from patients with various gynecologic and non-gynecologic diseases. Clin Biochem. 2011, 44: 884-888.","journal-title":"Clin Biochem"},{"key":"730_CR32","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/1465-9921-7-61","volume":"7","author":"L Bingle","year":"2006","unstructured":"Bingle L, Cross SS, High AS: WFDC2 (HE4): a potential role in the innate immunity of the oral cavity and respiratory tract and the development of adenocarcinomas of the lung. Respir Res. 2006, 7: 61-","journal-title":"Respir Res"},{"key":"730_CR33","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1002\/jcla.20329","volume":"23","author":"Z Xi","year":"2009","unstructured":"Xi Z, LinLin M, Ye T: Human epididymis protein 4 is a biomarker for transitional cell carcinoma in the urinary system. J Clin Lab Anal. 2009, 23: 357-361.","journal-title":"J Clin Lab Anal"},{"key":"730_CR34","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.ygyno.2007.10.017","volume":"108","author":"RG Moore","year":"2008","unstructured":"Moore RG, Brown AK, Miller MC: The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol. 2008, 108: 402-408.","journal-title":"Gynecol Oncol"},{"key":"730_CR35","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.ygyno.2008.08.031","volume":"112","author":"RG Moore","year":"2009","unstructured":"Moore RG, McMeekin DS, Brown AK: A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol. 2009, 112: 40-46.","journal-title":"Gynecol Oncol"},{"key":"730_CR36","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ygyno.2008.04.041","volume":"110","author":"LJ Havrilesky","year":"2008","unstructured":"Havrilesky LJ, Whitehead CM, Rubatt JM: Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence. Gynecol Oncol. 2008, 110: 374-382.","journal-title":"Gynecol Oncol"},{"key":"730_CR37","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.ygyno.2010.02.005","volume":"117","author":"B Nolen","year":"2010","unstructured":"Nolen B, Velikokhkatnaya L, Marrangoni A: Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass. Gynecol Oncol. 2010, 117: 440-445.","journal-title":"Gynecol Oncol"},{"key":"730_CR38","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1200\/JCO.2008.19.2484","volume":"28","author":"Z Yurkovetsky","year":"2010","unstructured":"Yurkovetsky Z, Skates S, Lomakin A: Development of a multimarker assay for early detection of ovarian cancer. J Clin Oncol. 2010, 28: 2159-2166.","journal-title":"J Clin Oncol"},{"key":"730_CR39","doi-asserted-by":"publisher","first-page":"e232","DOI":"10.1371\/journal.pmed.0050232","volume":"5","author":"M Kobel","year":"2008","unstructured":"Kobel M, Kalloger SE, Boyd N: Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med. 2008, 5: e232-","journal-title":"PLoS Med"},{"key":"730_CR40","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1097\/IGC.0b013e3182070f17","volume":"21","author":"GJ Rustin","year":"2011","unstructured":"Rustin GJ, Vergote I, Eisenhauer E, Pujade-Lauraine E, Quinn M: Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA125 agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer. 2011, 21: 419-423.","journal-title":"Int J Gynecol Cancer"},{"issue":"5","key":"730_CR41","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1002\/ijc.26129","volume":"130","author":"Y Park","year":"2012","unstructured":"Park Y, Kim Y, Lee EY, Lee JH, Kim HS: Reference ranges for HE4 and CA125 in a large Asian population by automated assays and diagnostic performances for ovarian cancer. Int J Cancer. 2012, 130 (5): 1136-1144.","journal-title":"Int J Cancer"},{"key":"730_CR42","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.ygyno.2011.02.022","volume":"121","author":"F Jacob","year":"2011","unstructured":"Jacob F, Meier M, Caduff R, Goldstein D, Pochechueva T: No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting. Gynecol Oncol. 2011, 121: 487-491.","journal-title":"Gynecol Oncol"},{"issue":"5","key":"730_CR43","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1097\/IGC.0b013e31821a3726","volume":"21","author":"X Chang","year":"2011","unstructured":"Chang X, Ye X, Dong L, Cheng H, Cheng Y: Human epididymis protein 4 (HE4) as a serum tumor biomarker in patients with ovarian carcinoma. Int J Gynecol Cancer. 2011, 21 (5): 852-858.","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"730_CR44","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.ejogrb.2011.05.021","volume":"158","author":"J Paek","year":"2011","unstructured":"Paek J, Lee SH, Yim GW, Lee M, Kim YJ: Prognostic significance of human epididymis protein 4 in epithelial ovarian cancer. Eur J Obstet Gynecol Reprod Biol. 2011, 158 (2): 338-342.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"730_CR45","doi-asserted-by":"crossref","first-page":"5535","DOI":"10.1200\/jco.2008.26.15_suppl.5535","volume":"26","author":"J Allard","year":"2008","unstructured":"Allard J, Somers E, Theil R, Moore RG: Use of a novel biomarker HE4 for monitoring patients with epithelial ovarian cancer. J Clin Oncol. 2008, 26: 5535-","journal-title":"J Clin Oncol"}],"container-title":["Diagnostic Pathology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1746-1596-8-11\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1746-1596-8-11.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1746-1596-8-11.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,20]],"date-time":"2020-07-20T23:15:04Z","timestamp":1595286904000},"score":1,"resource":{"primary":{"URL":"https:\/\/diagnosticpathology.biomedcentral.com\/articles\/10.1186\/1746-1596-8-11"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1,23]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["730"],"URL":"https:\/\/doi.org\/10.1186\/1746-1596-8-11","relation":{},"ISSN":["1746-1596"],"issn-type":[{"value":"1746-1596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,23]]},"article-number":"11"}}